Sinopharm (company)
Headquarters | |||||||
| Sinopharm | |||||||
| Company type | state-owned enterprise | ||||||
| Founded | November 26, 1998 | ||||||
| Headquarters | 20 Zhichun Road, Haidian District, Beijing , China | ||||||
Area served | China, exported worldwide | ||||||
Key people | Liu Jingzhen (Chairman & Chinese Communist Party Committee Secretary) | ||||||
| Revenue | CN¥247.110 billion (2014) | ||||||
| CN¥8.758 billion (2014) | |||||||
| CN¥2.705 billion (2014) | |||||||
| Total assets | CN¥199.192 billion (2014) | ||||||
| Total equity | CN¥31.944 billion (2014) | ||||||
| Owner | Chinese central government (100%) | ||||||
| Parent | SASAC of the State Council | ||||||
| Subsidiaries |
| ||||||
| Chinese name | |||||||
| Simplified Chinese | 中国医药集团总公司 | ||||||
| Traditional Chinese | 中國醫藥集團總公司 | ||||||
| |||||||
| short Chinese name | |||||||
| Simplified Chinese | 国药集团 | ||||||
| Traditional Chinese | 國藥集團 | ||||||
| |||||||
| Footnotes / references in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards | |||||||
China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.), Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai), and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).
China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.
Sinopharm was ranked 109th in the 2021 Fortune Global 500 list.